Bisphosphonate use does not impact survival in patients with pancreatic cancer: A propensity score matching analysis

Keyphrases

• Pancreatic Cancer 100%
• Propensity Score Analysis 100%
• Bisphosphonate Use 100%
• Statins 83%
• Bisphosphonates 83%
• Pancreatic Ductal Adenocarcinoma 66%
• Hazard Ratio 33%
• Confidence Interval 33%
• Non-associated 33%
• Improved Survival 33%
• Mevalonate Pathway 33%
• Mean Survival Time 16%
• Medicare 16%
• Propensity Score 16%
• Overall Survival 16%
• Cox Proportional Hazards Model 16%
• Surveillance Epidemiology 16%
• Statin Use 16%
• Charlson Comorbidity Index 16%
• Survival Benefit 16%
• Staged Treatment 16%
• Antineoplastic Properties 16%
• Kaplan-Meier 16%
• Survival Duration 16%
• Sociodemographic Characteristics 16%
• Linked Database 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Pancreas Cancer 100%
• Bisphosphonic Acid Derivative 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 45%
• Pancreas Adenocarcinoma 36%
• Mevalonic Acid 18%
• Overall Survival 9%
• Statin (Protein) 9%
• Comorbidity 9%

Biochemistry, Genetics and Molecular Biology

• Statin 100%
• Mevalonate Pathway 33%
• Overall Survival 16%
• Comorbidity 16%